Every day, humanity generates a digital ocean of data so vast that it is impossible to navigate without occasionally losing our way. Amidst this torrent of information, we encounter truth, nuance, and, inevitably, misinformation. Crucially, the experts who study this landscape remind us that “misinformation” is not always a product of malicious intent or hidden agendas. Often, it is simply the byproduct of human error—well-meaning people sharing ideas they genuinely believe, yet which are factually incomplete or incorrect. Understanding why this happens, and how it ripples through our social and technological networks, has become one of the most vital areas…

The rapidly evolving landscape of weight-loss and diabetes management has centered almost entirely on a new class of medications known as GLP-1 agonists. As these drugs—specifically Novo Nordisk’s Wegovy and Ozempic, and Eli Lilly’s Zepbound and Mounjaro—have reached a level of cultural ubiquity once reserved for blockbuster consumer tech, the competition between their manufacturers has intensified. What began as a clinical battle for efficacy and market share has now spilled over into the courtroom. Novo Nordisk has formally launched a lawsuit against Eli Lilly, alleging that the Indiana-based pharmaceutical giant is saturating the airwaves with marketing campaigns that are not…